Novo Nordisk, the maker of Ozempic and Wegovy, has filed a lawsuit in the US accusing rival Eli Lilly of false advertising by suggesting its weight-loss drugs are superior. The Danish company claims Eli Lilly's nationwide ad campaigns "intentionally" compared the highest approved doses of its own medicines—Mounjaro and Zepbound—with lower doses of Novo Nordisk's products, while omitting newer, higher-dose options.
The Lawsuit
According to BBC News, Novo Nordisk filed the lawsuit in the US on Tuesday, alleging that Eli Lilly's advertising campaigns "created the misleading impression that Eli Lilly's medicines are superior." The suit claims Eli Lilly committed "multiple violations" of federal and state false advertising and unfair competition laws.
Novo Nordisk said the ads "deceptively" presented Eli Lilly's products as superior while burying or omitting "critical clinical context." Specifically, the comparisons targeted are:
- Mounjaro vs. Ozempic
- Zepbound vs. Wegovy
"As new and more effective treatment options become available, people deserve accurate information that reflects the latest scientific evidence and helps them make informed care decisions," said John F. Kuckelman, senior vice president and group general counsel for Novo Nordisk. "Healthcare companies have a responsibility to keep their public claims accurate and current - ineffective, fine-print disclaimers do not fix the misleading impression created by major national campaigns."
Novo Nordisk is seeking a court order requiring Eli Lilly to pull its ads and instead run a "corrective advertising campaign." The company added that if Eli Lilly does not voluntarily remove the commercials, it will file a motion in the coming days to seek a preliminary injunction to block them.
Market Context
BBC reported that the lawsuit comes as Novo Nordisk and Eli Lilly are locked in a battle to dominate the fast-growing weight-loss drug industry, especially in the US. Analysts have estimated the market could be worth more than $100bn by 2030. The two pharmaceutical giants are the leading players in the GLP-1 receptor agonist class of drugs, which are used for type-2 diabetes and obesity.
| Drug (Eli Lilly) | Drug (Novo Nordisk) | Indication |
|---|---|---|
| Mounjaro | Ozempic | Type-2 diabetes |
| Zepbound | Wegovy | Obesity |
Implications for Pharmaceutical Manufacturing
While the lawsuit is a legal and marketing dispute, it highlights the intense competition in the GLP-1 manufacturing space. Both companies have been scaling up production to meet surging demand. For manufacturing executives and procurement professionals in the pharmaceutical supply chain, this legal action signals that aggressive market tactics may spill over into production and supply decisions. The outcome could affect how manufacturers position their products and communicate with healthcare providers and patients.
Sources:
